Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis
who have previously had an inadequate response to at least one TNF inhibitor either due to
lack of efficacy or an adverse event.